Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2070]

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )

Comment: Enfortumab vedotin is an effective therapy and important development...

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )

Novel methods of drug testing and biopsy in India

Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India

Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )

Myeloma highlights from EHA 2019

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Myeloma highlights from EHA 2019 ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )

AlloHCT conditioning intensity in AML in complete remission with residual...

Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda...

AlloHCT conditioning intensity in AML in complete remission with residual disease ( Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA )

Inhibition of NADK strongly inhibits T-ALL cells from growing

Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK

Inhibition of NADK strongly inhibits T-ALL cells from growing ( Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK )

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory...

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

Imetelstat provides durable transfusion independence in heavily transfused non...

Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France

Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS ( Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France )

Intervention for AML patients with MRD can result in improved survival

Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart...

Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced...

Dr Tira Tan - National Cancer Centre, Singapore

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer ( Dr Tira Tan - National Cancer Centre, Singapore )

More from ecancer